These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25645644)

  • 1. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
    D'Ambrosio R; Aghemo A; Colombo M
    Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
    Prescrire Int; 2015 Dec; 24(166):285-9. PubMed ID: 26788571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.
    Fazel Y; Lam B; Golabi P; Younossi Z
    Expert Opin Drug Saf; 2015 Aug; 14(8):1317-26. PubMed ID: 26043900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
    Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir as backbone of interferon free treatments.
    Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
    Omata M; Nishiguchi S; Ueno Y; Mochizuki H; Izumi N; Ikeda F; Toyoda H; Yokosuka O; Nirei K; Genda T; Umemura T; Takehara T; Sakamoto N; Nishigaki Y; Nakane K; Toda N; Ide T; Yanase M; Hino K; Gao B; Garrison KL; Dvory-Sobol H; Ishizaki A; Omote M; Brainard D; Knox S; Symonds WT; McHutchison JG; Yatsuhashi H; Mizokami M
    J Viral Hepat; 2014 Nov; 21(11):762-8. PubMed ID: 25196837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.
    Mangia A; Piazzolla V
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S179-85. PubMed ID: 25458780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir for the treatment of chronic hepatitis C virus infection.
    Temesgen Z; Talwani R; Rizza SA
    Drugs Today (Barc); 2014 Jun; 50(6):421-34. PubMed ID: 24983590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
    Younossi ZM; Stepanova M; Henry L; Gane E; Jacobson IM; Lawitz E; Nelson D; Nader F; Hunt S
    J Hepatol; 2014 Apr; 60(4):741-7. PubMed ID: 24333184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
    Rodríguez-Torres M
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1269-79. PubMed ID: 24215243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging treatments for hepatitis C.
    Flisiak R; Jaroszewicz J; Parfieniuk-Kowerda A
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):461-75. PubMed ID: 24102413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of the therapeutic strategy in hepatitis C: features of sofosbuvir and indications.
    Alberti A; Piovesan S
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S174-8. PubMed ID: 25458777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir (Sovaldi) for the treatment of hepatitis C.
    Lam B; Henry L; Younossi Z
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):555-66. PubMed ID: 24918162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir for the treatment of hepatitis C virus.
    Asselah T
    Expert Opin Pharmacother; 2014 Jan; 15(1):121-30. PubMed ID: 24289735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
    Younossi ZM; Stepanova M; Zeuzem S; Dusheiko G; Esteban R; Hezode C; Reesink HW; Weiland O; Nader F; Hunt SL
    J Hepatol; 2014 Aug; 61(2):228-34. PubMed ID: 24713186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the treatment of hepatitis C.
    Dhingra A; Kapoor S; Alqahtani SA
    Discov Med; 2014 Oct; 18(99):203-8. PubMed ID: 25336034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rapid evolution of treatment strategies for hepatitis C.
    Muir AJ
    Am J Gastroenterol; 2014 May; 109(5):628-35; quiz 636. PubMed ID: 24732866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.